Scott Vota, DO
Neurology · Richmond, VANPI 1497782320
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Tanabe Pharma America, Inc. at 25.8% of the total. Reporting peaked in 2020 at $3,896 and has fallen 91.3% since, to $340 in 2025.
Across 209 payments — averaging $41.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tanabe Pharma America, Inc.$2K
- Biogen$1K
- AbbVie$827
- AstraZeneca$565
- Novartis$392
- Amgen$347
- plus $3K from 34 others
Across 7 payments — averaging $8153.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Catalyst Pharmaceuticals, Inc.$42K
- Mallinckrodt Enterprises LLC$12K
- Octapharma USA, Inc.$3K
What the payments were for
- Consulting fees$3,29038%
- Food & beverage$5,16160%
- Education$2002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tanabe Pharma America, Inc. | 7 | $2,233 |
| Biogen | 10 | $1,316 |
| AbbVie(2 entities) | 65 | $827 |
| AstraZeneca(2 entities) | 8 | $565 |
| Novartis | 27 | $392 |
| Amgen(2 entities) | 9 | $347 |
| SK Life Science, Inc. | 5 | $288 |
| Lundbeck LLC | 3 | $230 |
| Kyowa Kirin, Inc. | 6 | $183 |
| Neurelis, Inc. | 2 | $179 |
| UCB, Inc. | 8 | $178 |
| EMD Serono, Inc. | 5 | $177 |
| Teva Pharmaceuticals USA, Inc. | 5 | $158 |
| Greenwich Biosciences, Inc. | 4 | $156 |
| Biohaven Pharmaceuticals, Inc. | 2 | $138 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $124 |
| ANI Pharmaceuticals, Inc. | 1 | $116 |
| Livanova USA, Inc. | 5 | $105 |
| Sunovion Pharmaceuticals Inc. | 1 | $90 |
| TG Therapeutics, Inc. | 1 | $86 |
| Argenx US, Inc. | 1 | $83 |
| Corium, LLC | 3 | $77 |
| Genentech USA, Inc. | 4 | $75 |
| Sanofi | 3 | $69 |
| Pfizer | 3 | $60 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Johnson & Johnson(2 entities) | 2 | $48 |
| Insightec,inc | 1 | $35 |
| Bristol Myers Squibb | 2 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| CSL Behring | 1 | $24 |
| Banner Life Sciences, LLC | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Abbott | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| GE HealthCare | 1 | $18 |
| Resmed Corp | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Adamas Pharmaceuticals, Inc. | 1 | $17 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,651 in reported general payments places this provider in the 75th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 22 | $203,386 |
| Trokendi XrTopiramate | 13 | $32,513 |
| XcopriCenobamate | 12 | $13,600 |
| Emgality PenGalcanezumab-Gnlm | 11 | $9,119 |
| Gabapentin | 75 | $2,689 |
| Mycophenolate Mofetil | 20 | $2,609 |
| Pyridostigmine Bromide | 28 | $2,138 |
| Primidone | 37 | $1,368 |
| Lacosamide | 12 | $1,365 |
| Fentanyl | 11 | $1,259 |
| Donepezil Hcl | 103 | $1,039 |
| Memantine Hcl | 31 | $789 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 30 | $668 |
| Pregabalin | 29 | $466 |
| Duloxetine Hcl | 14 | $420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $288 | $13,60012 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $29 | $4,74748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 neurology providers in Virginia.
Other neurology in Richmond
- Catherine HamRichmond$603K
- Daniel HardyRichmond$382K
- Myla GoldmanRichmond$132K
- Alan SchulmanRichmond$104K
- Warren FeltonRichmond$96K
- John WittmanRichmond$61K
- Matthew BoyceRichmond$56K
- Leslie CloudRichmond$46K
- Jonathan BekensteinRichmond$37K
- Jessica LehositRichmond$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.